BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 112 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q1 2021. The put-call ratio across all filers is 1.11 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,078,405 | -48.8% | 375,751 | -9.9% | 0.00% | 0.0% |
Q2 2023 | $2,106,249 | +143377.5% | 417,079 | -46.3% | 0.00% | 0.0% |
Q1 2023 | $1,468 | +55.5% | 776,594 | +48.0% | 0.00% | 0.0% |
Q4 2022 | $944 | -99.8% | 524,557 | +51.2% | 0.00% | – |
Q3 2022 | $586,000 | -3.8% | 346,980 | +40.2% | 0.00% | – |
Q2 2022 | $609,000 | -58.0% | 247,540 | -9.0% | 0.00% | -100.0% |
Q4 2021 | $1,450,000 | -30.2% | 272,035 | +10.8% | 0.00% | 0.0% |
Q3 2021 | $2,077,000 | -48.1% | 245,517 | -25.2% | 0.00% | -50.0% |
Q2 2021 | $4,000,000 | +17.2% | 328,158 | +133.3% | 0.00% | 0.0% |
Q1 2021 | $3,412,000 | -38.6% | 140,630 | -18.9% | 0.00% | -50.0% |
Q4 2020 | $5,555,000 | +378.1% | 173,330 | +350.9% | 0.00% | +300.0% |
Q3 2020 | $1,162,000 | +96.9% | 38,444 | +174.9% | 0.00% | 0.0% |
Q2 2020 | $590,000 | +154.3% | 13,986 | +50.5% | 0.00% | 0.0% |
Q1 2020 | $232,000 | – | 9,296 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
NEA Management Company, LLC | 3,449,845 | $8,487,000 | 0.44% |
Hawkeye Capital Management, LLC | 243,009 | $598,000 | 0.33% |
Boxer Capital, LLC | 2,014,858 | $4,957,000 | 0.31% |
Newtyn Management, LLC | 520,000 | $1,279,000 | 0.24% |
Artal Group S.A. | 1,646,517 | $4,050,000 | 0.22% |
DAFNA Capital Management LLC | 313,600 | $771,000 | 0.21% |
RA Capital Management | 2,589,904 | $6,371,000 | 0.17% |
Bellevue Group AG | 4,717,113 | $11,605,000 | 0.16% |
MPM BioImpact LLC | 239,888 | $590,000 | 0.16% |
K2 PRINCIPAL FUND, L.P. | 507,652 | $1,249,000 | 0.14% |